Intravenous versus subcutaneous EPO: anything to do with pure red cell aplasia complication

Am J Kidney Dis. 2003 Jan;41(1):266-7; author reply 267. doi: 10.1053/ajkd.2003.50072.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Erythropoietin / administration & dosage*
  • Humans
  • Injections, Intravenous / adverse effects
  • Injections, Intravenous / methods
  • Injections, Subcutaneous / adverse effects
  • Injections, Subcutaneous / methods
  • Recombinant Proteins
  • Red-Cell Aplasia, Pure / etiology*

Substances

  • Recombinant Proteins
  • Erythropoietin